Get the Stockscreener App
112.83
1.28%
1.45
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Merck Co Inc stock is traded at $112.83, with a volume of 4.05M.
It is up +1.28% in the last 24 hours and down -5.26% over the past month.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
See More
Previous Close:
$111.38
Open:
$111.43
24h Volume:
4.05M
Relative Volume:
0.43
Market Cap:
$278.55B
Revenue:
$65.51B
Net Income/Loss:
$8.93B
P/E Ratio:
31.75
EPS:
3.5532
Net Cash Flow:
$14.12B
1W Performance:
+1.37%
1M Performance:
-5.26%
6M Performance:
+16.98%
1Y Performance:
+48.31%
1-Day Range:
$110.97
$112.89
1-Week Range:
$110.94
$114.06
52-Week Range:
$75.40
$125.14
Merck Co Inc Stock (MRK) Company Profile
Name
Merck Co Inc
Sector
Industry
Phone
908-740-4000
Address
126 EAST LINCOLN AVENUE, RAHWAY, NJ
Compare MRK vs LLY, JNJ, ABBV, NVS, AZN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRK
Merck Co Inc
|
112.78 | 275.09B | 65.51B | 8.93B | 14.12B | 3.5532 |
LLY
Lilly Eli Co
|
986.76 | 896.13B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
229.62 | 545.74B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
209.41 | 371.72B | 62.82B | 3.60B | 19.98B | 2.0274 |
NVS
Novartis Ag Adr
|
149.35 | 282.55B | 54.66B | 13.58B | 16.05B | 7.0171 |
AZN
Astrazeneca Plc
|
184.27 | 281.60B | 60.48B | 10.40B | 8.05B | 3.3297 |
Merck Co Inc Stock (MRK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Feb-13-26 | Upgrade | Deutsche Bank | Hold → Buy |
| Jan-08-26 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-18-25 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Nov-24-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Oct-13-25 | Resumed | Citigroup | Neutral |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Feb-18-25 | Downgrade | Deutsche Bank | Buy → Hold |
| Feb-10-25 | Downgrade | TD Cowen | Buy → Hold |
| Jan-08-25 | Downgrade | Truist | Buy → Hold |
| Dec-20-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Dec-04-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-11-24 | Downgrade | Daiwa Securities | Buy → Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Mar-11-24 | Downgrade | Societe Generale | Hold → Sell |
| Jan-04-24 | Upgrade | TD Cowen | Market Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Buy |
| Oct-27-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Oct-20-23 | Upgrade | UBS | Neutral → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Hold |
| Apr-13-23 | Upgrade | Citigroup | Neutral → Buy |
| Mar-28-23 | Downgrade | Societe Generale | Buy → Hold |
| Mar-13-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Mar-06-23 | Initiated | Jefferies | Buy |
| Feb-22-23 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-04-23 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Oct-10-22 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-14-22 | Upgrade | Berenberg | Hold → Buy |
| Jul-06-22 | Upgrade | Daiwa Securities | Neutral → Buy |
| Jun-06-22 | Resumed | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Dec-17-21 | Initiated | Goldman | Buy |
| Dec-16-21 | Initiated | Daiwa Securities | Neutral |
| Dec-13-21 | Downgrade | UBS | Buy → Neutral |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Dec-07-21 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-29-21 | Downgrade | Citigroup | Buy → Neutral |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Nov-01-21 | Upgrade | Argus | Hold → Buy |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-27-21 | Resumed | Truist | Buy |
| May-20-21 | Downgrade | Argus | Buy → Hold |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Aug-03-20 | Upgrade | Goldman | Neutral → Buy |
| Jun-12-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-16-19 | Initiated | SVB Leerink | Outperform |
| Jul-03-19 | Initiated | Mizuho | Buy |
| May-28-19 | Initiated | Goldman | Neutral |
| May-13-19 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-16-18 | Reiterated | Citigroup | Buy |
| Oct-09-18 | Resumed | Guggenheim | Buy |
| Apr-23-18 | Upgrade | Goldman | Neutral → Buy |
| Apr-17-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-05-18 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-12-18 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| Feb-14-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-07-18 | Reiterated | Morgan Stanley | Equal-Weight |
| Jan-16-18 | Upgrade | SunTrust | Hold → Buy |
View All
Merck Co Inc Stock (MRK) Latest News
Merck & Co. Inc. stock (US58933Y1055): oncology growth meets new M&A financing - AD HOC NEWS
Merck's drug helps uterine cancer patients live longer in late-stage trial - Reuters
Why Is Regeneron Stock Sinking Monday? - Benzinga
L & S Advisors Inc Increases Stake in Merck & Co., Inc. $MRK - MarketBeat
Canada Post Corp Registered Pension Plan Acquires 35,631 Shares of Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. stock (US58933Y1055): Keytruda momentum and fresh earnings keep big pharma in focu - AD HOC NEWS
Financial Security Advisor Inc. Raises Holdings in Merck & Co., Inc. $MRK - MarketBeat
Lockheed Martin Investment Management Co. Has $9.87 Million Stock Holdings in Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. $MRK Shares Acquired by Convergence Investment Partners LLC - MarketBeat
Merck & Co., Inc. $MRK Stake Reduced by ANTIPODES PARTNERS Ltd - MarketBeat
Merck & Co. Inc. stock underperforms Friday when compared to competitors - MarketWatch
Merck & Co. Inc. stock (US58933Y1055): Key cancer franchise drives fresh earnings spotlight - AD HOC NEWS
Merck & Co., Inc. stock (US58933Y1055): pharma giant doubles down on M&A as investors eye post-Keytr - AD HOC NEWS
Merck & Co., Inc. $MRK Stock Holdings Increased by Phoenix Financial Ltd. - MarketBeat
Merck & Co., Inc. $MRK is Conning Inc.'s 5th Largest Position - MarketBeat
Bessemer Group Inc. Increases Holdings in Merck & Co., Inc. $MRK - MarketBeat
Allworth Financial LP Grows Stake in Merck & Co., Inc. $MRK - MarketBeat
Mondrian Global Equity Value Fund's Merck & Co Inc(MRK) Holding History - GuruFocus
Merck & Co., Inc. stock (US58933Y1055): Latest developments and business overview - AD HOC NEWS
Merck & Co. Inc. stock (US58933Y1055): Latest developments and business overview - AD HOC NEWS
Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
World Investment Advisors Buys 20,067 Shares of Merck & Co., Inc. $MRK - MarketBeat
Rayburn West Financial Services LLC Takes $1.17 Million Position in Merck & Co., Inc. $MRK - MarketBeat
Summit Wealth Group LLC Co. Has $522,000 Stock Position in Merck & Co., Inc. $MRK - MarketBeat
Bank Julius Baer & Co. Ltd Zurich Buys 100,280 Shares of Merck & Co., Inc. $MRK - MarketBeat
Top Companies in Hospital Acquired Infection Treatment MarketMerck & Co Inc, Pfizer Inc, Cipla Ltd etc. - openPR.com
Merck & Co. Inc. stock (US58933Y1055): Q1 results show revenue growth amid Keytruda strength - AD HOC NEWS
Merck & Co., Inc. stock (US58933Y1055): Q1 beat and upgraded 2026 guidance drive 8% jump - AD HOC NEWS
Merck & Co. Inc. stock (US58933Y1055): Q1 earnings beat with revenue growth - AD HOC NEWS
Merck's (NYSE:MRK) Soft Earnings Are Actually Better Than They Appear - Moomoo
VIRGINIA RETIREMENT SYSTEMS ET Al Reduces Position in Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. $MRK Stake Lifted by Independent Advisor Alliance - MarketBeat
Merck & Co., Inc. $MRK Shares Sold by Money Concepts Capital Corp - MarketBeat
MRK Stock Quote Price and Forecast - CNN
Merck & Co., Inc. (MRK) 10K Form and Latest SEC Filings 2026 - MarketBeat
Analyst Reinstates Merck (MRK) with ‘Neutral’ Rating, $125 Price Target - Insider Monkey
Merck & Co. stock (US58933Y1055): Oncology portfolio advances at ASCO 2026 - AD HOC NEWS
The Zacks Analyst Blog UnitedHealth, Merck & Co., Qualcomm, EVI and Optex - Zacks Investment Research
Merck (MRK) Tops Quarterly Sales Forecasts as Keytruda Drives Growth - Insider Monkey
Top Research Reports for UnitedHealth, Merck & Qualcomm - Yahoo Finance Singapore
Merck stock (US58933Y1055): Q1 earnings beat, revenue guidance narrowed - AD HOC NEWS
Merck & Co., Inc. stock (US58933Y1055): Q1 earnings beat with revenue growth - AD HOC NEWS
Merck & Co., Inc. $MRK Shares Sold by SVB Wealth LLC - MarketBeat
Swiss Life Asset Management Ltd Raises Position in Merck & Co., Inc. $MRK - MarketBeat
Erasca Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate ERAS-0015 in Combination with KEYTRUDA® (Pembrolizumab) - The Manila Times
Investors Can Find Comfort In Merck's (NYSE:MRK) Earnings Quality - Yahoo Finance Singapore
Securian Asset Management Inc. Has $7.10 Million Position in Merck & Co., Inc. $MRK - MarketBeat
NewEdge Wealth LLC Has $9.33 Million Stock Position in Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. $MRK Shares Sold by ABN AMRO Bank N.V. - MarketBeat
Osprey Private Wealth LLC Raises Stock Position in Merck & Co., Inc. $MRK - MarketBeat
Applied Finance Dividend Fund's Merck & Co Inc(MRK) Holding History - GuruFocus
Merck Co Inc Stock (MRK) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.23%
1.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):